References in periodicals archive ?
In one study, GGF2 was administered one hour following a permanent middle cerebral artery occlusion (MCAO) preclinical stroke model.
The company is also pursuing preclinical studies in other cardiac and neurological applications for GGF2 and other neuregulin growth factors.
The GGF2 Phase 1 clinical trial in heart failure was completed.
These data confirm earlier preclinical study results showing that GGF2 can improve recovery of function following stroke.
In August, the Company presented preclinical data at the World Meeting on Sexual Medicine that showed treatment with GGF2 improved erectile dysfunction (ED) following cavernous nerve injury.